Anstey Michael 4
4 · BICYCLE THERAPEUTICS plc · Filed May 30, 2019
Insider Transaction Report
Form 4
Anstey Michael
Director
Transactions
- Conversion
Series B2 Preferred Shares
2019-05-28+229,741→ 0 total(indirect: By Cambridge Innovation Capital (Jersey) Limited)→ Ordinary Shares (229,741 underlying) - Conversion
Ordinary Shares
2019-05-28+1,081,823→ 1,081,823 total(indirect: By Cambridge Innovation Capital (Jersey) Limited) - Exercise of In-Money
Ordinary Shares
2019-05-28+125,587→ 1,207,410 total(indirect: By Cambridge Innovation Capital (Jersey) Limited) - Conversion
Ordinary Shares
2019-05-28+229,741→ 1,437,151 total(indirect: By Cambridge Innovation Capital (Jersey) Limited) - Purchase
Ordinary Shares
2019-05-28$14.00/sh+314,286$4,400,004→ 1,751,437 total(indirect: By Cambridge Innovation Capital (Jersey) Limited) - Conversion
Series B1 Preferred Shares
2019-05-28+1,081,823→ 0 total(indirect: By Cambridge Innovation Capital (Jersey) Limited)→ Ordinary Shares (1,081,823 underlying) - Exercise of In-Money
Series B1 Preferred Shares Warrants
2019-05-28+125,587→ 0 total(indirect: By Cambridge Innovation Capital (Jersey) Limited)→ Ordinary Shares (125,587 underlying)
Footnotes (3)
- [F1]Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.
- [F2]The shares are held by Cambridge Innovation Capital (Jersey) Limited. The Reporting Person is a member of our Board of Directors and an investment director at Cambridge Innovation Capital plc.
- [F3]Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering.